NEWARK BETH ISRAEL MEDICAL CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1900-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
6
Active:0
Completed:2
Trial Phases
2 Phases
Phase 3:1
Phase 4:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 4
4 (80.0%)Phase 3
1 (20.0%)Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
Not yet recruiting
- Conditions
- Hemophilia A
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT06104826
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
SPG Block for Acute Pediatric Migraine
Phase 3
- Conditions
- Sphenopalatine NeuralgiaMigraine in ChildrenMigraine in Adolescence
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT03984045
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?
Phase 4
Completed
- Conditions
- Sickle Cell Anemia Crisis
- Interventions
- Drug: Normal saline
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 71
- Registration Number
- NCT03541980
- Locations
- 🇺🇸
Newark Beth Israel, Newark, New York, United States
Once-a-day Tacrolimus Conversion Study: The OneTAC Trial
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT02545972
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
Phase 4
- Conditions
- SmokingAcute Coronary Syndrome
- Interventions
- Drug: control
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01170338
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
- Prev
- 1
- 2
- Next
News
No news found